INT143686

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 2007
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 4
Total Number 4
Disease Relevance 0.83
Pain Relevance 2.16

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (CYP2D6) small molecule metabolic process (CYP2D6) oxidoreductase activity (CYP2D6)
endoplasmic reticulum (CYP2D6)
Anatomy Link Frequency
white blood cells 2
CYP2D6 (Homo sapiens)
Pain Link Frequency Relevance Heat
narcan 3 98.64 Very High Very High Very High
fluoxetine 4 93.24 High High
cocaine 2 92.60 High High
Morphine 13 91.12 High High
tramadol 2 90.40 High High
Nortriptyline 2 89.84 High High
Dextromethorphan 2 88.60 High High
Codeine 8 87.32 High High
antagonist 44 81.64 Quite High
opiate 1 78.40 Quite High
Disease Link Frequency Relevance Heat
Pressure Volume 2 Under Development 1 94.76 High High
Hypersensitivity 1 72.16 Quite High
Headache 5 70.68 Quite High
Vomiting 111 67.84 Quite High
Dizziness 2 62.04 Quite High
Constipation 3 61.28 Quite High
Post-operative Nausea 59 50.00 Quite Low
Sleep Disorders 2 5.00 Very Low Very Low Very Low
Pain 2 5.00 Very Low Very Low Very Low
Anxiety Disorder 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Furthermore, exposure of white blood cells to 10(-6) M S-nitroso-N-acetyl-DL-penicillamine (SNAP), a nitric oxide (NO) donor, reduced the expression of CYP2D6 and COMT.
Negative_regulation (reduced) of Gene_expression (expression) of CYP2D6 in white blood cells
1) Confidence 0.58 Published 2008 Journal Addict Biol Section Abstract Doc Link 17573783 Disease Relevance 0 Pain Relevance 0.97
The most significant difference observed was a consistent but substrate-dependent decease in the catalytic efficiencies of cDNA-expressed CYP2D6.10 and CYP2D6.17 compared with CYP2D6.1, yielding 1.32 to 27.9 and 7.33 to 80.4% of the efficiency of CYP2D6.1, respectively.
Negative_regulation (decease) of Gene_expression (cDNA-expressed) of CYP2D6
2) Confidence 0.43 Published 2007 Journal Drug Metab. Dispos. Section Abstract Doc Link 17470523 Disease Relevance 0 Pain Relevance 0.50
The most significant difference observed was a consistent but substrate-dependent decease in the catalytic efficiencies of cDNA-expressed CYP2D6.10 and CYP2D6.17 compared with CYP2D6.1, yielding 1.32 to 27.9 and 7.33 to 80.4% of the efficiency of CYP2D6.1, respectively.
Negative_regulation (decease) of Gene_expression (cDNA-expressed) of CYP2D6
3) Confidence 0.43 Published 2007 Journal Drug Metab. Dispos. Section Abstract Doc Link 17470523 Disease Relevance 0 Pain Relevance 0.50
Palonosetron does not cause inhibition or induction of the main hepatic enzyme systems including CYP2D6, CYP1A2 and CYP3A4/5, so the risk of significant drug interactions is low.119 However an adverse reaction with apomorphine that presented as profound hypotension and altered consciousness has been reported, so concomitant use is contraindicated.128


Negative_regulation (inhibition) of Gene_expression (/) of CYP2D6 associated with pressure volume 2 under development
4) Confidence 0.24 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697527 Disease Relevance 0.83 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox